Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound

The Eli Lilly & Co. logo at the company's Digital Health Innovation Hub facility in Singapore, on Thursday, Nov. 14, 2024.Eli Lilly on Thursday said its closely watched obesity pill helped patients maintain the majority of their weight loss after they switched directly from taking the company's injection Zepbound and Novo Nordisk's rival shot Wegovy in a late-stage trial. The company also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for obesity. T ...